Key result
Shuangshen Xionglian Granule reduces aortic plaque burden in preclinical atherosclerosis by suppressing EndMT.
Why the study?
The anti-atherosclerotic effects of Shuangshen Xionglian Granule and its role in modulating endothelial-to-mesenchymal transition in atherosclerosis were investigated.
Does Shuangshen Xionglian Granule (SSXL) attenuate atherosclerosis and endothelial-to-mesenchymal transition in preclinical models?
Does Shuangshen Xionglian Granule (SSXL) attenuate atherosclerosis and endothelial-to-mesenchymal transition in preclinical models?
Answers are grounded in this paper and cite their sources.
SSXL demonstrates potential as a multi-target therapeutic candidate for vascular protection in atherosclerosis by suppressing EndMT through the FGFR1-TGF-β/Smad2 axis.
Shuangshen Xionglian Granule (SSXL), a multi‐herb traditional Chinese medicine used for atherosclerosis (AS), was investigated for its anti‐atherosclerotic effects and its role in modulating endothelial‐to‐mesenchymal transition (EndMT). In high‐fat diet–fed ApoE −/− mice, SSXL ameliorated dyslipidemia, reduced systemic inflammation, and alleviated aortic plaque burden. An integrated approach combining UPLC–QTOF–MS profiling, network pharmacology, and transcriptomics identified 401 SSXL‐responsive disease‐associated genes, which were enriched in pathways related to TGF‐β, MAPK, cAMP, and extracellular matrix organization. In both aortic tissues from these mice and TGF‐β2–stimulated human aortic endothelial cells, SSXL preserved endothelial identity and suppressed EndMT. Mechanistically, SSXL restored FGFR1 phosphorylation while concomitantly downregulating TGF‐βRI/TGF‐β2 expression and Smad2 phosphorylation. Pharmacological inhibition of FGFR1 with PD173074 partially abrogated these protective effects, indicating that SSXL suppresses EndMT, at least in part, through FGFR1‐mediated inhibition of the TGF‐β/Smad2 signaling axis. These findings suggest that SSXL ameliorates AS through combined lipid‐lowering, anti‐inflammatory, and anti‐EndMT actions, supporting its potential as a multi‐target therapeutic candidate for vascular protection in AS.
No takes yet. Share an insight, caveat, or question.
Cui et al. (2026) studied Atherosclerosis. Shuangshen Xionglian Granule (SSXL) was evaluated on Endothelial-to-mesenchymal transition (EndMT) and atherosclerotic plaque burden. Shuangshen Xionglian Granule ameliorated dyslipidemia, reduced inflammation, and alleviated aortic plaque burden in ApoE -/- mice by suppressing EndMT via the FGFR1-TGF-β/Smad2 axis.
Synapse has enriched 10 related papers. Consider them for comparative context: